Pfizer licenses USD 650m upfront Innovent oncology portfolio in USD 10.5b deal

Pfizer has committed USD 650 million upfront to license a portfolio of 12 early-stage oncology programs from Innovent Biologics (HKEX: 01801), in a deal that could reach USD 10.5 billion in total value including milestones — one of the largest China-originated oncology licensing transactions on record. The agreement, announced May 28, covers antibody-drug conjugates (ADCs) with novel payloads and multispecific antibodies, with Innovent leading Phase I development across all programs before Pfizer assumes global development leadership. Pfizer (NYSE: PFE) will also propose four discovery-stage programs for Innovent to generate using its proprietary platforms, embedding a research collaboration within the broader licensing structure.

Under the tiered deal, Innovent receives the USD 650 million upfront plus up to USD 9.85 billion in development, regulatory, and commercial milestones, with double-digit royalties on net sales of exclusively licensed products. The 12 programs are divided into three tiers: four co-developed globally with profits shared in the US and Europe (Innovent retaining Greater China rights); four programs where Pfizer holds an exclusive ex-Greater China license; and four with an exclusive global Pfizer license. Closing remains subject to regulatory approvals.

Deal context

The portfolio spans two of Innovent's proprietary ADC platforms and a next-generation immuno-oncology bispecific design. Innovent's SoloTx platform produces topoisomerase I inhibitor-payload ADCs with site-specific conjugation, generating a controlled drug-to-antibody ratio designed to improve the therapeutic index relative to stochastic conjugation methods used in earlier-generation ADCs. Lead SoloTx programs include IBI354, an anti-HER2 ADC in Phase III, and IBI343, targeting CLDN18.2 in Phase I for gastric and pancreatic cancers.

The DuetTx platform — described by Innovent as the world's first dual-payload ADC technology to reach human trials — loads two mechanistically distinct cytotoxic agents onto a single antibody, with the intent of delivering combination chemotherapy at the single-cell level and circumventing resistance pathways that can emerge against single-payload ADCs. The CEACAM5-targeted IBI3020, the lead DuetTx candidate with a dual TOP1 and MMAE payload, is in Phase I in the US and China.

The most clinically advanced named asset is IBI363, a PD-1/IL-2α-bias bispecific fusion protein described by Innovent as designed to preferentially deliver IL-2 signaling to tumor-infiltrating T cells already engaging PD-1, while reducing systemic IL-2 toxicity by de-biasing binding away from the IL-2Rβ/γ receptor subunits responsible for vascular leak syndrome seen with recombinant IL-2. Innovent has received US FDA IND approval for a global Phase III study of IBI363 in squamous non-small cell lung cancer, and the molecule has generated clinical signals in MSS colorectal cancer — a subtype historically unresponsive to PD-1 monotherapy.

Industry and transaction context

The USD 650 million upfront is a significant figure for a portfolio at predominantly Phase I and discovery stage, but still not the largest struck by Innovent with a multinational partner. For comparison, Innovent's collaboration with Lilly announced in February 2026 — which covered oncology and immunology programs — carried a reported USD 350 million upfront and a total potential deal value of USD 8.5 billion. Meanwhile, an October 2025 partnership with Takeda covering IO and ADC molecules included USD 1.2 billion upfront and up to USD 11.4 billion in biobuck commitments.

Pfizer's decision to embed four discovery-stage programs — where it proposes targets and Innovent applies its discovery engine — reflects a sourcing model in which large pharma effectively outsources early oncology discovery to Chinese biotechs with established platform infrastructure, rather than building equivalent capabilities internally. This mirrors a broader industry pattern: Western pharma has increasingly used Chinese partners as discovery and Phase I execution engines, particularly in ADCs, where Chinese companies have developed differentiated linker-payload and conjugation technologies at scale.

The deal's timing reflects Pfizer's need to rebuild its oncology pipeline amid pending patent cliffs and post-COVID portfolio rationalization. Pfizer Oncology has publicly identified ADCs, multispecific antibodies, and small molecules as its three core mechanistic pillars — the Innovent portfolio maps directly onto two of those three. With 12 programs spanning both modalities, the collaboration gives Pfizer optionality across a range of targets and stages without committing to late-stage development costs upfront, since Innovent bears Phase I expenses before the handoff.

Innovent, which reported revenue surpassing RMB 10 billion (approximately USD 1.4 billion) in 2025 and described itself as entering an era of profitability and globalization, has now executed major licensing transactions with Lilly, Roche, Takeda, and Pfizer within roughly 18 months — a sequencing that suggests a deliberate effort to monetize its discovery engine across multiple large pharma relationships simultaneously rather than committing exclusively to a single global partner.

---

Spot something wrong? Report an issue with this article